Potential therapeutic use of relaxin in accelerating closure of cranial bone defects in mice.

Physiol Rep · 2019 · PMC6545299 · PMID 31155858

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

As shown in Table 1 , there were borderline significant or significant differences between rhRLX and vehicle treatments for lesion closure (vehicle 54.3 vs. relaxin 45.8%), BV/TV (vehicle 25.6 vs. relaxin 21.9%), and BMD (vehicle 0.351 vs. relaxin 0.310 g/cm 3 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.